Honing Treatment Strategies in Advanced Prostate Cancer: Latest Evidence to Guide Clinical Practice

Interact with an expert during this 1-hour, CME/CE/CPE-certified live meeting focused on current best practices for managing advanced prostate cancer including hormone-sensitive metastatic disease, non-metastatic and metastatic CRPC.


  • Introduction
  • Advances in Nonmetastatic Castration-Resistant Prostate Cancer
  • Current Approaches for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer
  • Treating Metastatic Castration-Resistant Prostate Cancer
  • Emerging Approaches on the Horizon
  • Final Thoughts and Audience Q&A


Date / Time
Event Details


Robert Dreicer, MD, MS, MACP, FASCO

Section Head, Medical Oncology
Associate Director for Clinical Research
Deputy Director
University of Virginia Cancer Center
Co-Director, Paul Mellon Urologic Institute
Professor of Medicine and Urology
University of Virginia School of Medicine

Charles J. Ryan, MD

Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
 Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Goal Statement
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating recent findings into the treatment of patients with prostate cancer.

Target Audience
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with advanced prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan optimal, individualized therapeutic strategies for patients with advanced or metastatic prostate cancer through exposure to expert insights and recommendations, real-world experience, and evidence-based and consensus-based guidelines
  • Evaluate new therapeutic options for nonmetastatic castration-resistant prostate cancer
  • Compare combinations of ADT with various agents vs ADT alone for metastatic hormone-sensitive prostate cancer
  • Apply expert recommendations for the sequencing of available and emerging hormonal, cytotoxic, immunologic, bone-directed, molecularly targeted, and other novel therapies (alone and in combination) to safely and effectively integrate them into the care of patients with metastatic castration-resistant prostate cancer
  • Assess and manage the risk for cardiotoxicity or bone loss prior to and/or during prostate cancer treatment
  • Refer appropriate patients with prostate cancer to ongoing clinical trials assessing novel therapies alone and in combination throughout the disease continuum to aid in trial enrollment

Learning objectives apply to all professions.


USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Continuing Medical Education

Credit Designation

USF Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nursing Continuing Education

USF Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing nursing education activity.

Pharmacist Continuing Education

USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This application-based program has been approved for 1.0 contact hour (0.1 CEU). Universal program number is as follows: 0230-9999-20-021-L01-P.

For Pharmacists:
It is the responsibility of the pharmacy participant to ensure the provider has the learner’s birthday and e-Profile ID (ePID)/NABP number; it is the responsibility of the provider to submit to CPE Monitor participant information within 60 days of the activity for all participants who have attended, attested to their participation, and provided their ePID/NABP number and birthdate. 

ACPE indicates it is the responsibility of the pharmacy professional to confirm the status of their NABP contact hours before 60 days past the activity. If there are any discrepancies, contact the provider immediately. You may contact USF Health through cpdsupport@usf.edu.

Disclosure of Conflicts of Interest 
USF Health adheres to ACCME, ANCC, and ACPE Standards regarding commercial support of continuing medical education. It is the policy of USF Health that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

The information provided at this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

If you have any questions relating to the continuing education accreditation of this activity, please contact USF Health at 813-224-7860 or cpdsupport@usf.edu.